日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Reply to Chan: Identification of Alpha-1 Antitrypsin-Deficient Subjects with Normal Spirometry Who May Benefit from Alpha-1 Antitrypsin Replacement

回复 Chan:识别肺功能正常的α1-抗胰蛋白酶缺乏症患者,这些患者可能受益于α1-抗胰蛋白酶替代疗法

Fraughen, Daniel D; Ghosh, Auyon J; Carroll, Tomás P; McElvaney, Noel G

Optimising bronchoalveolar lavage: lessons from alpha-1 antitrypsin deficiency

优化支气管肺泡灌洗:从α1-抗胰蛋白酶缺乏症中汲取的经验教训

Herron, Malcolm; Roche, Suzanne; Fraughen, Daniel D; Heeney, Ronan C; Kanchi, Lasya; Leacy, Emma J; Casey, Michelle; Gunaratnam, Cedric; Carroll, Tomás P; Murphy, Mark P; McElvaney, Noel G

Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis

一项多国注册研究分析表明,针对重度α1-抗胰蛋白酶缺乏症的增强疗法可提高生存率,且与肺功能下降无关。

Fraughen, Daniel D; Ghosh, Auyon J; Hobbs, Brian D; Funk, Georg-Christian; Meischl, Tobias; Clarenbach, Christian F; Sievi, Noriane A; Schmid-Scherzer, Karin; McElvaney, Oliver J; Murphy, Mark P; Roche, Adam D; Clarke, Louise; Strand, Matthew; Vafai-Tabrizi, Florian; Kelly, Geraldine; Gunaratnam, Cedric; Carroll, Tomás P; McElvaney, Noel G

A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19

一项随机、双盲、安慰剂对照的静脉注射 α-1 抗胰蛋白酶治疗 COVID-19 继发 ARDS 的试验

Oliver J McElvaney, Natalie L McEvoy, Fiona Boland, Oisín F McElvaney, Grace Hogan, Karen Donnelly, Oisín Friel, Emmet Browne, Daniel D Fraughen, Mark P Murphy, Jennifer Clarke, Orna Ní Choileáin, Eoin O'Connor, Rory McGuinness, Maria Boylan, Alan Kelly, John C Hayden, Ann M Collins, Ailbhe Cullen,